Calamos Advisors
VRTX icon

Calamos Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Calamos Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-31,000
Closed -$5.14M – 722
2018
Q4 		$5.14M Buy
+31,000
New +$5.37M 0.03% 435

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Calamos Advisors's VRTX Position: Q2 2026 in Review

Calamos Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q2 2026, selling an estimated $1.11M and leaving 75,388 shares worth $37.4M. The position accounts for 0.12% of the portfolio, ranked #170.

Calamos Advisors first reported a position in VRTX in Q4 2013 and has held it in 38 quarters since. The position peaked at $49.9M in Q2 2020. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Calamos Advisors held 75,388 shares of Vertex Pharmaceuticals worth $37.4M as of Q2 2026.
  • Calamos Advisors sold 2,498 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
  • Vertex Pharmaceuticals made up 0.12% of Calamos Advisors's portfolio in Q2 2026, its #170 holding.
  • Calamos Advisors first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 38 quarters since.
  • Calamos Advisors's Vertex Pharmaceuticals position peaked at $49.9M in Q2 2020.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.